A federal judge’s ruling restricts compounding pharmacies from producing generic Zepbound, sparking concerns over affordability

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their medications elsewhere.

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and diabetes drugs Zepbound and Mounjaro in the United States.

Medications like Mounjaro and Wegovy have been hailed as "game changers" for tackling obesity.

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly diving into the opportunity to make anti-obesity products. This article looks into key players in the arena.

Whether you have type 2 diabetes, obesity or just a few extra pounds that you’d like some help shedding, chances are you’re one of the millions of adults worldwide who heard about Novo Nordisk’s remarkable brand name drug Ozempic and how it can help you reduce your body weight.

Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range of doses sold online to try to stave off competition from compounding pharmacies and rival Novo Nordisk .

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs.

Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs.